Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Elicera Therapeutics AB is a biotechnology company focused on advancing innovative cancer therapies. Specializing in immuno-oncology, Elicera Therapeutics AB is dedicated to harnessing the body's immune system to target and eliminate cancer cells. Their core technology platform, iTANK (ImmunoTherapies Activated by the NKG2D-pathway), aims to enhance the efficacy of CAR T-cells, an emerging class of cancer treatment that offers targeted attacks on tumor cells. Operating within the burgeoning biotech sector, Elicera Therapeutics AB plays a pivotal role in developing next-generation cancer therapies. The company's research and clinical trials are integral to breakthroughs in personalized medicine and have significant implications for patient outcomes. Since its inception, Elicera Therapeutics AB has contributed to the growing field of cancer immunotherapy, which promises to revolutionize how complex cancer cases are treated globally. As such, this company's endeavors are vital to the biomedical community's continuous quest for more effective cancer solutions.
kr 0.22
+kr 0.00 (+0.93%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 22M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 14M
▼ -8.0% YoY
Op. Margin
—
ROIC
-64.25%
▲ +18.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 28M
▲ +8.1% YoY
Op. Cash Flow (TTM)
-kr 23M
▲ +9.6% YoY
Net Debt
-kr 25M
Net Cash Position
Cash & Equiv.
kr 25M
Continue Research
Elicera Therapeutics AB (ELIC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Elicera Therapeutics AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Elicera Therapeutics AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -64.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ELIC.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.